共 50 条
- [1] Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia[J]. BLOOD, 2017, 130Irwin, DebraSzabo, ErikaPathak, AshutoshTang, Boxiong
- [2] ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA[J]. VALUE IN HEALTH, 2016, 19 (03) : A248 - A248Lachaine, J.Kouroukis, C. T.
- [3] BENDAMUSTINE AND RITUXIMAB AS FIRST OR SECOND LINE THERAPY IN ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)[J]. HAEMATOLOGICA, 2014, 99 : 592 - 592Gozzetti, A.Ciolli, S.Candi, V.Breschi, C.Fabbri, A.Schiattone, L.Cencini, E.Papini, G.Raspadori, D.Defina, M.Aprile, L.Bosi, A.Bocchia, M.
- [4] Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab[J]. LEUKEMIA RESEARCH, 2019, 79 : 17 - 21Spacek, MartinObrtlikova, PetraHrobkova, StanislavaCmunt, EduardKarban, JosefMolinsky, JanSimkovic, MartinMocikova, HeidiMohammadova, LekaaPanovska, AnnaNovak, JanTrneny, MarekSmolej, LukasDoubek, Michael
- [5] Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) : 3 - 19Itchaki, GiladBrown, Jennifer R.
- [6] Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : E269 - E272Morabito, FortunatoTripepi, GiovanniDel Poeta, GiovanniMauro, Francesca RomanaReda, GianluigiSportoletti, PaoloLaurenti, LucaCoscia, MartaHerishanu, YairBossio, SabrinaVarettoni, MarziaMurru, RobertaChiarenza, AnnalisaVisentin, AndreaCondoluci, AdalgisaMoia, RiccardoPietrasanta, DanielaLoseto, GiacomoConsoli, UgoScortechini, IlariaRossi, Francesca MariaZucchetto, AntonellaAl-Janazreh, HamdiVigna, ErnestoMartino, Enrica AntoniaCassin, RamonaDArrigo, GraziellaGalimberti, SaraRago, AngelaAngeletti, IlariaBiagi, AnnalisaDel Giudice, IlariaBomben, RiccardoNeri, AntoninoFronza, GilbertoMonti, PaolaMenichini, PaolaOlivieri, JacopoCutrona, GiovannaRossi, DavideCuneo, AntonioDi Raimondo, FrancescoGaidano, GianlucaPolliack, AaronTrentin, LivioFoa, RobinFerrarini, ManlioGattei, ValterGentile, Massimo
- [7] Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Irwin, Debra E.Thompson, StephenRibalov, RinatChoudhry, Azhar
- [8] Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study[J]. TERAPEVTICHESKII ARKHIV, 2017, 89 (07): : 57 - 64Stadnik, E. A.Strugov, V. V.Andreeva, T. O.Virts, Yu. V.Rumyantsev, A. M.Mirolyubova, Yu. V.Butylin, P. A.Zaritsky, A. Yu.
- [9] Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 623 - 628Irwin, DebraWilson, KathleenThompson, StephenChoudhry, Azhar
- [10] A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy[J]. MEDICAL MYCOLOGY CASE REPORTS, 2020, 27 : 17 - 21Eichenberger, Emily M.Saullo, JenniferBrander, DanielleWang, Shih-HsiuPerfect, John R.Messina, Julia A.